Abstract
Several options are available to address hemostasis at the end of a cardiac catheterization or percutaneous transfemoral transcatheter aortic valve replacement (TAVR) when conventional options are ineffective. To date, there have been few studies exploring the use of a topical thrombin preparation, as one of its main contraindications is that it cannot be used intravascularly due to risk of embolization. The following case shows safe utilization of Surgiflo hemostatic gel matrix under fluoroscopic guidance against an inflated balloon in order to achieve closure of a fistulous tract from a femoral artery access site during percutaneous TAVR.
MeSH terms
-
Aged
-
Aortic Valve Stenosis / diagnosis
-
Aortic Valve Stenosis / physiopathology
-
Aortic Valve Stenosis / surgery*
-
Catheterization, Peripheral / adverse effects*
-
Catheterization, Peripheral / methods
-
Computed Tomography Angiography / methods
-
Cutaneous Fistula* / diagnosis
-
Cutaneous Fistula* / etiology
-
Cutaneous Fistula* / therapy
-
Femoral Artery* / diagnostic imaging
-
Femoral Artery* / surgery
-
Hemostasis, Surgical / methods*
-
Hemostatics / administration & dosage*
-
Humans
-
Male
-
Postoperative Hemorrhage* / diagnosis
-
Postoperative Hemorrhage* / etiology
-
Postoperative Hemorrhage* / therapy
-
Transcatheter Aortic Valve Replacement / adverse effects*
-
Transcatheter Aortic Valve Replacement / methods
-
Treatment Outcome
-
Ultrasonography, Doppler / methods
-
Vascular Fistula* / diagnosis
-
Vascular Fistula* / etiology
-
Vascular Fistula* / therapy